Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Immunome, Inc.NASDAQ: IMNM
Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026
Weighted avg shares (diluted) grows, but more slowly than its trailing trend
Q3 FY2026 weighted avg shares (diluted) of 113.56M shares rose 29.1% year over year, behind the +34.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +93.1% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +29.1% toward the trailing-twelve-month pace of +34.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 87.35M USD
- Year-over-year change
- +49.0%
- 4-year CAGR
- +65.9%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.35M | +49.0% |
| FY2024 | 2024-12-31 | 58.64M | +195.5% |
| FY2023 | 2023-12-31 | 19.84M | +63.6% |
| FY2022 | 2022-12-31 | 12.13M | +5.1% |
| FY2021 | 2021-12-31 | 11.54M | — |
Weighted Avg Shares (Diluted) vs competitors
How IMNM compares with its peers on the latest reported figures
- IMNM's LTM Sep 2026 weighted avg shares (diluted) of 106.83M shares is the 3rd highest of the 11 companies compared; the peer median is 66.33M shares.
- Its year-over-year change of +34.8% is the 2nd highest of 11, against a peer median of +11.2%.
- Over three fiscal years its annual growth of +93.1% compares with a peer median of +19.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 179.3M | +94.5% | +77.8% | |
| LTM Mar 2026 | 125.95M | +13.3% | +21.1% | |
| LTM Sep 2026 | 106.83M | +34.8% | +93.1% | |
| LTM Mar 2026 | 82.59M | +22.4% | +19.7% | |
| LTM Sep 2026 | 72.36M | +9.0% | +12.4% | |
| LTM Mar 2026 | 69.4M | +7.1% | +32.7% | |
| LTM Mar 2026 | 63.26M | +0.8% | +0.9% | |
| LTM Mar 2026 | 50.99M | -0.4% | +3.3% | |
| LTM Mar 2026 | 40.11M | +19.2% | +4.7% | |
| LTM Mar 2026 | 34.62M | +19.9% | +33.4% | |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding IMNM) | 66.33M | +11.2% | +19.2% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.